{
  "slug": "fucoxanthin",
  "name": "Fucoxanthin (Brown-algae xanthophyll)",
  "alternate_names": [
    "Allenic xanthophyll",
    "Fucoxanthinol (active metabolite)",
    "Brown seaweed carotenoid"
  ],
  "mechanism": [
    "UCP1 upregulation (white-to-brown adipocyte conversion signal)",
    "AMPK activation",
    "NRF2 antioxidant response",
    "NF-κB inhibition",
    "Anti-obesity adipokine modulation"
  ],
  "target": [
    "Visceral adipose tissue UCP1",
    "AMPK pathway",
    "Hepatic lipid metabolism",
    "Glucose homeostasis markers"
  ],
  "use_case": [
    "metabolic syndrome adjunct (research context)",
    "body weight markers",
    "hepatic lipid markers",
    "glucose tolerance signal"
  ],
  "body_system": [
    "ENDO",
    "METABOLISM",
    "LIVER",
    "CARDIO",
    "MITO"
  ],
  "evidence_tier": "C",
  "evidence_anchor_pmid_count": 55,
  "evidence_breakdown": {
    "meta_sr": 0,
    "human_rct": 1,
    "total_indexed": 55
  },
  "evidence_long_form_url": "https://asxan.ai/ingredients/fucoxanthin/",
  "dosage_range": "2.4-12 mg/day (often as combination formulation · Xanthigen-style trials use 2.4 mg/day for 16 weeks)",
  "safety_notes": "Generally well tolerated in published RCTs at 2.4-12 mg/day for 12-16 weeks · pregnancy/lactation data limited · iodine content varies by source seaweed (consider thyroid-sensitive individuals)",
  "regulatory": {
    "fda": "DSHEA dietary supplement · NDI varies by source · no FDA authorized health claim",
    "efsa": "No EU authorized health claim under Reg 432/2012 · novel food evaluation case-by-case for specific extraction processes",
    "anvisa": "RDC 243/2018 dietary supplement framework · IN 28/2018 alegação funcional not authorized for fucoxanthin specifically"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/fucoxanthin/",
  "related_goal_slugs": [
    "weight-management",
    "longevity-stack",
    "heart-health",
    "glp-1-companion"
  ],
  "related_lifestyle_slugs": [
    "keto",
    "intermittent-fasting",
    "senior-60-plus"
  ],
  "last_evidence_review": "2026-05-23",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-05-23",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}